CL2017000326A1 - Derivados de 6-alquinil-piridina como mimeticos de smac. - Google Patents

Derivados de 6-alquinil-piridina como mimeticos de smac.

Info

Publication number
CL2017000326A1
CL2017000326A1 CL2017000326A CL2017000326A CL2017000326A1 CL 2017000326 A1 CL2017000326 A1 CL 2017000326A1 CL 2017000326 A CL2017000326 A CL 2017000326A CL 2017000326 A CL2017000326 A CL 2017000326A CL 2017000326 A1 CL2017000326 A1 CL 2017000326A1
Authority
CL
Chile
Prior art keywords
smac mimetics
alkynyl
pyridine derivatives
aiquinil
piridine
Prior art date
Application number
CL2017000326A
Other languages
English (en)
Spanish (es)
Inventor
Ulrich Reiser
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2017000326A1 publication Critical patent/CL2017000326A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CL2017000326A 2014-08-11 2017-02-08 Derivados de 6-alquinil-piridina como mimeticos de smac. CL2017000326A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14180554 2014-08-11

Publications (1)

Publication Number Publication Date
CL2017000326A1 true CL2017000326A1 (es) 2017-10-20

Family

ID=51300621

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000326A CL2017000326A1 (es) 2014-08-11 2017-02-08 Derivados de 6-alquinil-piridina como mimeticos de smac.

Country Status (34)

Country Link
US (4) US9481673B2 (enExample)
EP (1) EP3180339B1 (enExample)
JP (1) JP6250226B2 (enExample)
KR (1) KR102445744B1 (enExample)
CN (2) CN111440164B (enExample)
AP (1) AP2017009718A0 (enExample)
AR (1) AR101479A1 (enExample)
AU (1) AU2015303308B2 (enExample)
BR (1) BR112017002498B1 (enExample)
CA (1) CA2956123C (enExample)
CL (1) CL2017000326A1 (enExample)
CO (1) CO2017001226A2 (enExample)
CY (1) CY1121273T1 (enExample)
DK (1) DK3180339T3 (enExample)
EA (1) EA031424B1 (enExample)
ES (1) ES2711763T3 (enExample)
HR (1) HRP20190336T1 (enExample)
HU (1) HUE043915T2 (enExample)
IL (1) IL249844B (enExample)
LT (1) LT3180339T (enExample)
ME (1) ME03303B (enExample)
MX (1) MX2017001835A (enExample)
NZ (1) NZ728073A (enExample)
PE (1) PE20170193A1 (enExample)
PH (1) PH12017500231A1 (enExample)
PL (1) PL3180339T3 (enExample)
PT (1) PT3180339T (enExample)
RS (1) RS58355B1 (enExample)
SG (1) SG11201700999YA (enExample)
SI (1) SI3180339T1 (enExample)
TR (1) TR201902023T4 (enExample)
TW (1) TWI723959B (enExample)
UA (1) UA118887C2 (enExample)
WO (1) WO2016023858A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR101479A1 (es) * 2014-08-11 2016-12-21 Boehringer Ingelheim Int Derivados de 6-alquinil-piridina
EA038950B1 (ru) 2016-05-19 2021-11-12 Бёрингер Ингельхайм Интернациональ Гмбх Способ получения производных 6-алкинил-пиридина
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
CN110475567A (zh) * 2017-03-31 2019-11-19 勃林格殷格翰国际有限公司 抗癌组合疗法
JP2022511437A (ja) 2018-11-26 2022-01-31 デバイオファーム インターナショナル エス.エー. Hiv感染の組み合わせ治療
TW202600150A (zh) 2019-01-25 2026-01-01 德商百靈佳殷格翰國際股份有限公司 編碼ccl21之重組棒狀病毒
AU2020356356A1 (en) 2019-09-25 2022-05-12 Debiopharm International S.A. Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma
BR112022023753A2 (pt) 2020-06-03 2022-12-20 Boehringer Ingelheim Int Rhabdovírus recombinante que codifica para uma proteína de fusão fc de domínio extracelular cd80
WO2024175554A1 (en) 2023-02-21 2024-08-29 Institut Curie Trail agonists for use in the treatment of cancer in patients having an activating alteration of fgfr3

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060234360A1 (en) * 2005-04-13 2006-10-19 Paola Branduardi Ascorbic acid production from D-glucose in yeast
AU2006255084A1 (en) 2005-06-08 2006-12-14 Novartis Ag Organic compounds
WO2007101347A1 (en) 2006-03-07 2007-09-13 Aegera Therapeutics Inc. Bir domain binding compounds
BRPI0720049A2 (pt) 2006-12-07 2014-01-07 Novartis Ag Derivados de piridina utilizados como inibidores de xiap
US8859541B2 (en) * 2012-02-27 2014-10-14 Boehringer Ingelheim International Gmbh 6-alkynylpyridines
US9249151B2 (en) 2013-08-23 2016-02-02 Boehringer Ingelheim International Gmbh Bis-amido pyridines
US9278978B2 (en) 2013-08-23 2016-03-08 Boehringer Ingelheim International Gmbh 6-Alkynyl Pyridine
AR101479A1 (es) * 2014-08-11 2016-12-21 Boehringer Ingelheim Int Derivados de 6-alquinil-piridina

Also Published As

Publication number Publication date
CA2956123C (en) 2023-02-14
UA118887C2 (uk) 2019-03-25
US9481673B2 (en) 2016-11-01
KR20170036095A (ko) 2017-03-31
AU2015303308A1 (en) 2017-02-02
BR112017002498A2 (pt) 2017-12-05
SG11201700999YA (en) 2017-03-30
BR112017002498B1 (pt) 2022-10-11
AP2017009718A0 (en) 2017-01-31
PH12017500231A1 (en) 2017-07-03
NZ728073A (en) 2022-10-28
TR201902023T4 (tr) 2019-03-21
ME03303B (me) 2019-07-20
JP2017524013A (ja) 2017-08-24
CN106573930A (zh) 2017-04-19
US20190358218A1 (en) 2019-11-28
JP6250226B2 (ja) 2017-12-20
CN111440164A (zh) 2020-07-24
US20170020859A1 (en) 2017-01-26
EP3180339B1 (en) 2018-12-05
US20180015082A1 (en) 2018-01-18
RS58355B1 (sr) 2019-03-29
PL3180339T3 (pl) 2019-05-31
SI3180339T1 (sl) 2019-03-29
CA2956123A1 (en) 2016-02-18
TWI723959B (zh) 2021-04-11
AU2015303308B2 (en) 2020-01-30
US10413536B2 (en) 2019-09-17
CO2017001226A2 (es) 2017-05-10
PT3180339T (pt) 2019-02-27
DK3180339T3 (en) 2019-03-04
MX2017001835A (es) 2017-04-27
ES2711763T3 (es) 2019-05-07
EP3180339A1 (en) 2017-06-21
US20160039814A1 (en) 2016-02-11
HUE043915T2 (hu) 2019-09-30
IL249844B (en) 2019-03-31
EA201790349A1 (ru) 2017-07-31
IL249844A0 (en) 2017-03-30
US9801871B2 (en) 2017-10-31
PE20170193A1 (es) 2017-03-25
CN106573930B (zh) 2020-03-03
CN111440164B (zh) 2023-02-17
HRP20190336T1 (hr) 2019-05-03
TW201619156A (zh) 2016-06-01
LT3180339T (lt) 2019-02-25
EA031424B1 (ru) 2018-12-28
WO2016023858A1 (en) 2016-02-18
AR101479A1 (es) 2016-12-21
KR102445744B1 (ko) 2022-09-20
CY1121273T1 (el) 2020-05-29

Similar Documents

Publication Publication Date Title
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CY1121413T1 (el) Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα
CR20190318A (es) Compuestos heterocíclicos como inmunomoduladores
CY1118859T1 (el) 6-αλκινυλο-πυριδινες ως μιμητες smac
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
UY36285A (es) Compuestos que inhiben la proteína mcl-1
MX380829B (es) Derivados de quinoxalina útiles como amortiguadaores de receptor del factor de crecimiento de fibroblastos (fgfr) cinasa.
UY35590A (es) Nuevos compuestos para el tratamiento del cáncer
CU20150062A7 (es) Lactamas n-(heteroarilo sustituido) fusionadas utiles en el tratamiento del crecimiento celular anormal
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
UY35711A (es) Bis-amidopiridinas como moduladores de la actividad de iap y sus usos como miméticos de smac
CL2016003214A1 (es) Derivados de la indolizina como inhibidores de las fosfoinositido-3 quinasas
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
CL2017000541A1 (es) Compuestos y composiciones como inhibidores de raf kinasa
BR112017003346B8 (pt) Derivados de pirazolopiridina, seus usos, e composição farmacêutica
CY1121273T1 (el) Παραγωγα 6-αλκυνυλο-πυριδινης ως smac μιμητικα
UY35710A (es) 6-alquinilpiridinas como moduladores de la actividad de iap y sus usos como miméticos de smac
CL2017000040A1 (es) Inhibidores de aldosterona sintasa.
MX2017001603A (es) Derivados de piperazina como moduladores de los receptores x del higado.
GT201500143A (es) Composiciones que comprenden vortioxetina y donepezilo campo tecnico
MX377528B (es) Compuestos de platino funcionalizados con monomaleimida para la terapia del cáncer.
UY35997A (es) Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
BR112018007358A2 (pt) derivados de 1,4-dicarbonil-piperidila